Defined Term    Location Clause Samples

Defined Term    Location. Estimated Capital Expenditures Deficit Section 2.2(a)(iii) Estimated Capital Expenditures Surplus Section 2.2(a)(iii) Estimated Cash on Hand Section 2.2(a)(ii) Estimated Company Indebtedness Section 2.2(a)(ii) Estimated Condemnations Amount Section 2.3(a)(iii) Estimated Harvest Report Section 2.3(a)(i) Estimated Land Sales Amount Section 2.3(a)(ii) Estimated Net Working Capital Section 2.2(a)(i) Estimated Net Working Capital Deficit Section 2.2(a)(i) Estimated Net Working Capital Surplus Section 2.2(a)(i) Estimated Jasper Remediation Cost Section 10.5(c)(i) Estimated Remediation Cost Section 6.8(b) Estimated Remediation Cost Threshold Excess Section 8.7(l) Estimated Sellers Transaction Expenses Section 2.2(a)(ii) Estimated Timber Adjustment Value Section 2.3(a)(i) Excluded Claims Section 14.12(c) External Equity Commitment Letters Section 5.7 External Equity Financing Sources Section 5.7 Final Capital Expenditures Adjustment Amount Section 2.2(d) Final Casualty Losses Amount Section 2.3(c)(iii) Final Condemnations Amount Section 2.3(b)(iii) Final ▇▇▇▇▇▇ Damages Amount Section 6.8(e) Final Land Sales Amount Section 2.3(b)(ii) Final Timber Adjustment Value Section 2.3(b)(i)(3) Final Timber Harvest Adjustment Section 2.3(b)(i)(3) Financial Statements Section 3.8 Financing Section 5.7 First Termination Fee Section 12.2(b) Governmental Consents Section 3.7(b)(i) GPT1 Preamble Harvest Objection Notice Section 2.3(b)(i) ▇▇▇▇▇▇ Damages Section 6.8(a) Indemnified Party Section 11.6 Indemnifying Party Section 11.6 Independent Accountant Section 2.2(b)(ii) Initial Title Commitments Section 7.6(a) Insurance Policies Section 3.16 Intellectual Property Section 3.15 Interim Payment Section 2.2(b)(i) Land Sales Amount Section 2.3(a)(ii) Latest Balance Sheet Section 3.8 Liquid Assets Threshold Section 11.12 Liquid Assets Threshold Period Section 11.12 LogCo Agreements Section 6.9 LogCo Assignments Section 6.9 LogCo and CP Parent LP Assignments Section 6.9 LogCo Components Section 3.8 LogCo Inc. Section 6.9 LogCo LLC Section 6.9 LogCo Terminations Section 6.9 Material Contract Section 3.12(a) Material Licenses and Permits Section 3.19(a) Minor Claim Section 11.8(a) New Stumpage Agreements Section 7.7 New Title Exceptions Section 7.6(c) Non-Disclosure Agreement Section 6.4(d) Nursery Asset Transfers Section 6.10 Outside Accountant Section 2.2(b) Outside Date Section 12.1(b) Parent Equity Commitment Letter Section 5.7 Parent Related Parties Section 12.2(e) Partial Interest Pa...

Defined Term    Location. Disclosing Party Section 12.1(a) Distributor Section 7.5 (c) Exclusivity Period Section 6.1 External Officer Section 15.7(a) External Expenses Section 2.1(d) Indemnitee Section 13.7(c) Indemnitor Section 13.7(c) Issuing Party Section 12.2(b) Joint Program IP Section 9.2(c) JSC Section 3.2(a) JWT Section 3.2(f) Losses Section 13.7(a) Milestone Events Section 8.2(a) Milestone Payments Section 8.2(a) Party Representatives Section 13.3 Payments Section 8.6(f) Product Development and Manufacturing Plan Section 2.1(b) Product Development and Manufacturing Term Section 2.1(a) Product Specific Patent Section 9.2(b) Program Lead Section 3.1 Quality Agreement Section 5.1 Receiving Party Section 12.1(a) Release Section 12.2(b) Reviewing Party Section 12.2(b) Royalty Term Section 8.3(b) Sole Program IP Section 9.2(c) Subcommittees Section 3.2(e) Supply Agreement Section 5.1 Term Section 14.1

Defined Term    Location. Issuing Party Section 12.1(b) Joint Sponsored Design/Preclinical Collaboration Technology Section 9.2(d)(iii) JRC Section 3.2(a) Losses Section 13.5(a) [***] License Section 4.1 [***] Section 4.1 Option Fee Section 8.2 Pfizer Compound Improvement Section 9.2(c) Pfizer Indemnitees Section 13.5(c) Pfizer Option Notice Section 4.1 Pfizer Option Period Section 4.1 Pfizer Sponsored Design/Preclinical Collaboration Technology Section 9.2(c)(i) [***] License Section 4.1 [***] Section 4.1 Product Specific Patent Section 10.1(c) Program Lead Section 3.1 Receiving Party Section 12.1(a) Release Section 12.1(b) Replacement Period Section 2.2(c) Reviewing Party Section 12.1(b) Royalty Term Section 8.8(b) Sole Sponsored Design/Preclinical Collaboration Technology Section 9.2(c)(i) Targeted Nanoparticle Section 1.1 Supply Agreement Section 6.1 Term Section 14.1

Defined Term    Location. Agreement Effective Date Consultant Client Parties Consultant’s Specialized Expertise USCIS EB‐5 Program U.S.

Defined Term    Location. Affected Party Section 13.7(f) Agreed Quarterly Budget Section 2.1(c) Arbitration Matter Section 15.7(b)(i) AstraZeneca Core IP Section 9.2(b) AstraZeneca Indemnitees Section 13.7(b) AstraZeneca Program IP Section 9.2(c) Bankruptcy Event Section 13.7(f) BIND Core IP Section 9.2(a) BIND Indemnitees Section 13.7(a) BIND Program IP Section 9.2(c) Claim Section 13.7(c) Competitive Infringement Section 11.1 Compound Claim Section 11.1 Confidential Information Section 12.1(a) Clinical Development & Commercialization Plan Section 4.1(c) Clinical Development & Commercialization Term Section 4.2(a) Confidentiality Agreement Section 12.5

Defined Term    Location. Company Stock Recital A Company Disclosure Letter Article IX Company Employees Article IX Company Financial Advisor Article IX Company Financial Statements Article IX Company Intellectual Property Article IX Company Knowledge Person Article IX Company Material Adverse Effect Article IX Company Material Contract Section 3.15(a) Company Option Plans Article IX Company Permits Article IX Company Products Article IX Company Purchase Plan Article IX Company Reports Article IX Company Required Vote Article IX Company Restricted Stock Unit Article IX Company Stockholders Recital B Company Stockholders Meeting Article IX Company Stock Option Article IX Company Stock Rights Article IX Company Termination Fee Article IX Company 10-K Article IX Confidentiality Agreement Article IX

Defined Term    Location. “Agreement” First Paragraph

Defined Term    Location. Delaware Secretary Article IX DGCL Recital A Dissenter Shares Article IX Effect Article IX Effective Time Article IX Employment Agreements Article IX Encumbrance Article IX Environmental Claims Article IX Environmental Laws Article IX Environmental Permits Article IX Equity Financing Section 4.5 Equity Financing Letter Section 4.5 ERISA Article IX Exchange Act Article IX Exchange Fund Section 2.1 FLSA Article IX FMLA Article IX GAAP Article IX Governmental Entity Article IX Hazardous Materials Article IX HSR Act Article IX Indemnified Persons Section 5.10(a) Intellectual Property Article IX IRS Article IX Knowledge Article IX Labor Laws Article IX Law Article IX Letter of Transmittal Section 2.2(a) Liabilities Article IX Merger Recital A Merger Consideration Section 1.4(a) Merger Sub Preamble Nasdaq Article IX NLRB Article IX Open Source Software Article IX Option Consideration Section 1.7(b) Order Article IX Outside Termination Date Section 7.1(f) Parent Preamble Parent Bylaws Article IX Parent Material Adverse Effect Article IX Parent Termination Fee Article IX Patent Article IX Paying Agent Article IX Permitted Encumbrance Article IX

Defined Term    Location. Additional Option Fee Section 8.5